Heather McArthur, MD
Clinical Director of Breast Oncology and Komen Distinguished Chair in Clinical Breast Cancer Research
University of Texas Southwestern Medical Center
Dallas, Texas, United States
Triple-negative breast cancer (TNBC) has historically been associated with significantly poor outcomes. With the expansion of immuno-oncology across the TNBC treatment landscape, immunotherapy has emerged as a main pillar of care, and immune checkpoint inhibitors (ICIs) have become powerful tools against this aggressive cancer type. Studies are under way to evaluate immunotherapy combinations and sequential strategies, as well as multimodal approaches that incorporate ICIs with radiotherapy, cryoablation, surgery, and various targeted agents. In addition to immunotherapy, targeted therapies such as antibody–drug conjugates (ADCs) and poly ADP-ribose polymerase (PARP) inhibitors are also emerging as effective agents in the metastatic setting.
This PeerView Live Seminars & Practicum will highlight important updates on the use of cancer immunotherapies and targeted agents in the management of patients with TNBC, including evidence supporting ICIs in earlier disease settings and advice for integrating novel immunotherapies and targeted therapies into practice. In addition, case-based scenarios will provide additional practical guidance on interprofessional and multidisciplinary approaches for effectively utilizing these therapies in the context of multimodal treatment.